Evidence map›Paper›PMID 42761567›Full record

ReviewPeerJ2026

Oropouche virus infection: an emerging arboviral threat in Asia.

Norhafizah Saari, Rafidah Hanim Shueb

Abstract readReview
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Norhafizah SaariDepartment of Medical Microbiology and Parasitology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
Rafidah Hanim ShuebDepartment of Medical Microbiology and Parasitology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oropouche virus (OROV), a neglected arbovirus of the Methodology: This narrative literature review was conducted using PubMed, Scopus, and Web of Science from September 2025 to May 2026. A total of 7,939 records were initially identified, and 105 relevant sources were selected based on their relevance to OROV virology, transmission dynamics, clinical manifestations, evolutionary potential, environmental drivers, and possible emergence in Asia. Results: Current evidence shows that OROV has progressed from a regionally neglected arbovirus to an emerging preparedness concern. Its segmented RNA genome enables reassortment, supporting viral adaptability and the emergence of strains such as OROVBR-2015-2024, which have been associated with enhanced transmission potential and more severe clinical outcomes. In Asia, potential emergence would likely result from multiple converging factors rather than a single determinant. These include the presence of diverse biting midges and mosquitoes that require vector competence assessment, climate conditions favourable to vector persistence, land-use change, urbanisation, increased wildlife-livestock-human contact, and frequent international travel. Clinical overlap with dengue, Zika, and chikungunya may further delay recognition, particularly in settings where OROV molecular testing is not routinely available. Conclusion: OROV emergence in Asia is not inevitable but remains a credible preparedness concern. Proactive surveillance, diagnostic readiness, vector competence studies, and regional preparedness are needed to enable early detection and reduce the risk of introduction and establishment.

Indexed as

Bunyaviridae InfectionsCommunicable Diseases, EmergingOrthobunyavirusAnimalsAsiaHumansArbovirusAsian countryOropouche virusSpread

Identifiers

PMID42761567
PMCPMC13588100

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.